Related Experiment Video
Updated: Jul 17, 2026
11:53
Cecal Ligation Puncture Procedure
Published on: May 7, 2011
Prostacyclin in sepsis: a systematic review
E M Zardi1, D M Zardi, A Dobrina
1Area of Internal Medicine and Immunology, University Campus Bio-Medico, Rome, Italy. e.zardi@unicampus.it
Prostaglandins & Other Lipid Mediators
|January 30, 2007
Summary
Infections disrupt body balance and weaken responses, even leading to septic shock. Prostacyclin, a vasodilator, may improve infection outcomes and protect the liver when used with antibiotics.
Area of Science:
- Vascular biology and pathophysiology
- Pharmacology
- Immunology
Background:
- Infective processes disrupt vascular hemodynamics and tissue antioxidant properties, altering homeostasis.
- This disruption can weaken the body's response to infection, potentially leading to ineffective treatment in cases like septic shock.
- Existing literature highlights the impact of infections on physiological and metabolic balance.
Purpose of the Study:
- To review mechanisms by which infections alter homeostasis.
- To explore the potential of prostacyclin and its analogs in managing infection-related complications.
- To assess the role of prostacyclin in improving outcomes for liver pathologies.
Main Methods:
- Literature review focusing on hemodynamic and anti-inflammatory properties of prostacyclin.
- Analysis of prostacyclin's effects in conjunction with anti-infective drugs.
- Examination of prostacyclin's cytoprotective and hemodynamic effects in liver transplantation and related pathologies.
Main Results:
- Prostacyclin and its analogs possess hemodynamic and anti-inflammatory properties that can prevent homeostatic changes during infection.
- While not directly anti-infective, prostacyclin may enhance the effectiveness of antibiotics in certain circumstances.
- Prostacyclin demonstrates cytoprotective effects on the liver and reduces ischemia-reperfusion damage, suggesting its utility in liver diseases.
Conclusions:
- Prostacyclin and its analogs offer a potential adjunctive therapy for infections by mitigating hemodynamic and homeostatic disturbances.
- Their use may improve the efficacy of conventional anti-infective treatments and protect organs like the liver.
- Further investigation into prostacyclin's role in managing sepsis and liver ischemia is warranted.
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:25Acute Inflammation III: Local and Systemic Effects
Acute inflammation produces a coordinated set of local and systemic changes that limit injury, eliminate pathogens, and initiate repair. These responses arise within minutes of infection, trauma, or chemical insult and are driven by vascular alterations and leukocyte-derived mediators. When the stimulus resolves, the reaction typically abates within days.Local EffectsAt the site of injury, arteriolar vasodilation increases blood flow, resulting in redness and warmth. Simultaneously, increased...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
01:29Pulmonary Embolism I: Introduction
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
01:19Pulmonary Embolism I: Introduction
A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...